As­traZeneca snaps up ra­dio­phar­ma part­ner for $2B up­front

As­traZeneca is bet­ting $2 bil­lion up­front to buy Fu­sion Phar­ma­ceu­ti­cals, join­ing a land grab in the bur­geon­ing ra­dio­phar­ma­ceu­ti­cals space.

The deal, which al­so in­cludes up to $400 mil­lion in con­tin­gent val­ue rights, un­der­scores As­traZeneca’s am­bi­tion of “re­plac­ing tra­di­tion­al reg­i­mens like chemother­a­py and ra­dio­ther­a­py with more tar­get­ed treat­ments” for can­cer, the British drug­mak­er wrote in a state­ment. It first teamed up with Fu­sion more than three years ago to de­vel­op next-gen­er­a­tion al­pha-emit­ting ra­dio­phar­ma­ceu­ti­cals and com­bi­na­tion ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.